The "Solidarity" trials to for clinical research for COVID-19 should be accompanied by strong sustainability and ethics. There is no room for error, nor verbose sidestepping. It is important to be clear, direct and efficient for the public.
* What will be done to assure diversity in trial reach for the six countries involved?
* Will the template for consent, IRB streamlining and other international work be formalized for continued use with future public health crises?
* What will partnerships look like for pharmaceutical companies involved? What will medical home models look like for follow up, etc, and who will assure benefits of sustained delivery post-trial?
* Rather than be moved around from location to location, forming and disrupting trusted community bonding, what will Solidarity trial planners do to assure long-term medical improvement build from these foundations? This includes local medical education, technological infrastructure support, pharmacy access, public health surveillance assistance, pharmaceutical corporate presence and allied health support in these countries.
https://www.who.int/publications/m/item/weekly-update-on-covid-19-9-october-2020
Comments
Post a Comment